Trendlines Group Ltd. · SGX:42T
Trendlines — The Trendlines Group — Q3 2017 Earnings Presentation
18 slides from Trendlines's earnings presentation, Nov 9, 2017
Slide 1: Financial highlights Q3 2017
Financial highlights Q3 2017 9 November 2017 SGX:42T OTCQX: TRNLY
Slide 2: Legal disclaimer
Legal disclaimer IMPORTANT NOTICE This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. (“Company”) or any of its portfo
Slide 3: Agenda
Agenda 1. Corporate highlights: Steve Rhodes, Chairman & CEO 2. Financial highlights: Gabi Heller, CFO 3. Post Q3 Developments: Todd Dollinger, Chairman & CEO 3
Slide 4: Corporate highlights
Corporate highlights
Slide 5: Value creation through portfolio expansion
Value creation through portfolio expansion Portfolio value with exit proceeds 120 100 Portfolio Value Cumulative Exit Proceeds 80 60 40 20 0 30.12.08 30.12.09 30.12.10 30.12.11 31.12.12 31.12.13 31.12.14 31.12.15 31.12.16 30.9.17 Portfolio value includes the fair value of investments in companies ac
Slide 6: Key corporate developments Q3 2017
Key corporate developments Q3 2017 • Increase of 12.4% in portfolio value from 31 December 2016 to US$94.0 million as at 30 September 2017 • Net profit after tax of US$3.0 million for third quarter ended 30 September 2017. • Joint venture established with Shoushan Wealth Holdings to help Trendlines’
Slide 7: Key portfolio company developments Q3 2017
Key portfolio company developments Q3 2017 • Two new companies created in Israel: BiPS Medical Ltd. and FruitSpec Ltd. • First new company for Trendlines Medical Singapore: InterVaal Pte. Ltd. • Five portfolio companies raise US$7.6 million, of which three rounds led by strategic investors • Two exi
Slide 8: 10 Companies to Watch
10 Companies to Watch* • ApiFix Ltd. • BioFishency Ltd. • EdenShield Ltd. • Escala Medical Ltd. • Fidmi Medical Ltd. • Gordian Surgical Ltd. • Leviticus Cardio Ltd. • MemTech Ltd. • Saturas Ltd. • Vensica Medical Ltd. *Updated report issued 19 October 2017; 10 Companies to Watch 8
Slide 9: Q3 Highlights from the "10 Companies to Watch" report
Q3 Highlights from the “10 Companies to Watch” report EdenShield • Raised US$2 million from strategic and financial investors • Strategic partnership announced with Kibbutz Yotvata in southern Israel to facilitate an increase in production Fidmi • Raised US$2 million investment from B. Braun Melsung
Slide 10: Financial highlights
Financial highlights
Slide 11: Consolidated condensed report of income
Consolidated condensed report of income 11
Slide 12: Key Components of Value (US$ million)
Key Components of Value (US$ million) Change in portfolio value during the year Balance sheet 12.4 (4.1) 14.2 (5.8) (4.8) (14.3) 1.9 (0.5) 83.7 94.0 82.7 Net portfolio Investment in FV increase FV decrease & Net portfolio Cash, short-term Non-recourse Deferred Deferred tax (2) Other Total equity val
Slide 13: Post Q3 Developments
Post Q3 Developments
Slide 14: October 2017 Placement of New Shares
October 2017 Placement of New Shares • 100 million new shares • Outstanding shares now 608.7 million • Pricing at S$0.1403 per share • Gross proceeds S$14.03 million (US$10.3 million) • Net proceeds S$13.34 million (US$ 9.8 million) 14
Slide 15: Key components of Placement
Key components of Placement • Shareholder base • Participation of B.Braun Melsungen AG • New institutional, corporate and individual investors • Greater liquidity • Use of Proceeds • Investments in new, prospective and existing portfolio companies • Working capital 15
Slide 16: Strategic Review and Expense Reduction Plan
Strategic Review and Expense Reduction Plan Objective: to reduce costs, increase efficiency and enhance shareholder value Target: reduce operating expenses for the financial year ending 31 December 2018 by approximately US$1.3 million, as compared to operating, general and administrative expenses (i
Slide 17: Dividend Policy
Dividend Policy It is the intention of the Board of Directors that dividends will be paid from the Company's annual distributable after tax profits out of net cash proceeds received by the Company from the following two sources: • payout ratio of 90% of dividend payments received by the Company from
Slide 18: SGX: 42T OTCQX: TRNLY www.trendlines.com
Todd Dollinger, Chairman & CEO SGX: 42T todd@trendlines.com OTCQX: TRNLY Steve Rhodes, Chairman & CEO +972.72.260.7000 steve@trendlines.com www.trendlines.com Gabi Heller, CFO gabi@trendlines.com Judith Kleinman Director IR & Corporate Communications 9 November 2017 judith@trendlines.com